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Abstract
While diagnosis has traditionally been viewed as an essential concept in medicine, particularly when selecting
treatments, we suggest that the use of diagnosis alone may be limited, particularly within mental health. The
concept of clinical case formulation advocates for collaboratively working with patients to identify idiosyncratic
aspects of their presentation and select interventions on this basis. Identifying individualized contributing factors,
and how these could influence the person’s presentation, in addition to attending to personal strengths, may allow
the clinician a deeper understanding of a patient, result in a more personalized treatment approach, and
potentially provide a better clinical outcome.
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Background
“In neurosis and personality disorders, formulation is a
clearer guide to aetiology, prognosis and treatment than
is categorical diagnosis” Aveline, p. 199 [1]
This paper describes concerns around using diagnosis
alone as a tool to select clinical interventions, provides
an overview of some current models of case formula-
tion, and examines its potential clinical utility.
The clinical utility of diagnosis and formulation
With debate and controversy already emerging around
some of the diagnoses proposed in the upcoming Diag-
nostic and Statistical Manual of Mental Disorders
(DSM), Fifth Edition, it may be timely to review the con-
cepts of diagnosis and formulation in mental health. Psy-
chiatry has traditionally emphasized the importance of
diagnostic categories, with the implication that these
offer a reliable guide for treatment options and prediction
of outcomes. Diagnosis has also been regarded histori-
cally as helpful from a research standpoint, allowing cate-
gorization of people by disorders in order to quantify
outcomes, and facilitate discussion around interventions
and etiology.
In reality, however, diagnosis alone may tell us little
about causation of a psychiatric disorder. Diagnosis may
also instruct us poorly about which form of intervention
we should undertake, and offers no information about the
person’s experience of their disorder. Kendell and Jablen-
sky [2] acknowledged that while diagnoses may be ‘...help-
ful working concepts for clinicians’ (p.4), many are not
‘valid’, in the sense that they are not ‘...discrete entities
with natural boundaries that separate them from other
disorders’ (p.4). Furthermore, Tarrier and Calam [3] noted
that, as diagnoses in the DSM and the International Clas-
sification of Diseases (ICD-10) are often based on selecting
from a list in which some items are present and others
absent, it is possible for two people to have the same diag-
nosis with few, and in some cases, no symptoms in
common.
Categorical diagnoses are perhaps most valuable for dis-
orders in which there is greater homogeneity, where bio-
marker studies show some demonstrable patterns, and
where categorical diagnosis guides treatment with a degree
of accuracy. Unfortunately, few disorders in psychiatry
match this description. Phenomena such as mood and per-
sonality disorders, psychoses, and anxiety disorders can be
associated with a diversity of etiological factors including
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early childhood experiences, trauma, personality styles,
family, interpersonal, lifestyle, medical, and social stressors,
with each factor playing a greater or lesser role for each
person. Understanding and incorporating these into an
individualized treatment plan is an essential part of quality
care, with failure to do so not only risking an ineffective
outcome, but potentially impacting negatively on the ther-
apeutic relationship and resulting in exacerbation of the
person’s symptomatology.
At least in part due to recognition of the limitations of
diagnosis in mental health, the concept of formulation or
case conceptualization has attracted increasing interest in
recent years. Formulation has been defined as synthesiz-
ing the patient’s experience with relevant clinical theory
and research [4], as ‘...the bridge between assessment and
treatment’ [[5], p.210] and has been utilized for multiple
disorders in children, adults and older adults. [6-8]. How-
ever, formulation may be particularly helpful for people
who have not had an adequate response to traditional
interventions, people who have Axis II disorders, or
when comorbidity complicates which interventions
should be utilized first [9,10].
Formulation can serve a number of functions. These
include: understanding significant etiological factors that
have influenced the person’s presentation; identifying key
difficulties; guiding which interventions should be uti-
lized and in what order; and anticipating challenges that
may occur during the course of treatment [4,6,7,11].
What should a formulation comprise? The ‘Five
P’s’ approach to formulation
Despite some differences between theoretical orientations,
some key themes exist around the content of formulations,
with one of the more popular recent approaches utilizing
the ‘Five Ps’. These are:
1. Presenting problem. This goes beyond diagnosis to
include what the person and clinician identify as difficul-
ties, how the person’s life is affected, and when a particu-
lar difficulty should be targeted for intervention. For
example, while a person may meet criteria for the diagno-
sis of borderline personality disorder, presenting difficul-
ties may include not being able to maintain employment,
erratic friendships, and physical health complications
resulting from self-harm. Specifying such difficulties can
allow for a more focused intervention.
2. Predisposing factors. This comprises identifying pos-
sible biological contributors (for example, organic brain
injury and birth difficulties), genetic vulnerabilities
(including family history of mental health difficulties),
environmental factors (such as socio-economic status,
trauma, or attachment history) and psychological or per-
sonality factors (including core beliefs or personality fac-
tors) which may put a person at risk of developing a
specific mental health difficulty.
3. Precipitating factors. This can include significant
events preceding the onset of the disorder, such as sub-
stance use, or interpersonal, legal, occupational, physical,
or financial stressors.
4. Perpetuating factors. This comprises factors which
maintain the current difficulties. These can include
ongoing substance use, repeating behavioral patterns
(including avoidance or safety behaviors in anxiety dis-
orders, or withdrawal in depressive disorders), biological
patterns (such as insomnia in mania, and insomnia or
hypersomnia in depression) or cognitive patterns such
as attentional biases, memory biases, or hypervigilance.
5. Protective/positive factors. This involves identifying
strengths or supports that may mitigate the impact of
the disorder. These can include social support, skills,
interests, and some personal characteristics. Kuyken et
al. [4] suggested that this is a particularly important ele-
ment which has traditionally been lacking in mental
health interventions, but inclusion of which results in a
higher likelihood of reduced symptomatology and
increased resilience (p.4). We would add that identifica-
tion of protective factors also creates increased opti-
mism in both the clinician and patient and contributes
to a positive therapeutic relationship.
Importantly, formulations should be flexible, and
should incorporate new information as it emerges. As
Persons [6] noted, ‘... assessment and treatment are a
continuous process of proposing, testing, re-evaluating,
revising, rejecting, and creating new formulations’ (p. 55).
Cautions Regarding Formulation
Despite numerous strengths, some caution is required
when using a formulation-based approach. Chadwick et
al. [12] reported that while most of their participants
reported an ‘...increased sense of hope and understand-
ing’ (p. 679) following formulation, some also described
negative aspects, including that it has been ‘saddening,
upsetting and worrying’ (p. 674). This study highlights
the importance of developing collaborative formulations
within a strong therapeutic relationship and at a reason-
able pace. We would also suggest that similar risks exist
when discussing diagnoses with patients. It is also notable
that the formulation undertaken in this study did not
include identifying participants’ strengths or protective
factors. It may be, therefore, that had protective factors
and strengths been included, the outcome could have
been better.
Notably, research on the impact of formulation on out-
come is still somewhat limited, and questions remain
regarding inter-rater reliability [4,13]. However, training
and therapist experience have consistently been found to
impact on the quality of formulations for clinicians work-
ing with either cognitive behavioral or psychodynamic
frameworks [14]. Encouragingly, Kendjelic & Eells [15]
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reported that even brief clinician training produced ‘...
formulations rated as higher in overall quality and as more
elaborated, comprehensive, complex, and precise’ (p.66).
Conclusions
When done well, formulation provides an opportunity for
a shared understanding of a person’s difficulties, and can
offer a way of answering the classic questions of ‘why this
person?’, ‘why this problem?’, and ‘why now?’ in ways that
diagnosis alone does not. Importantly, it can also provide
a rationale and shared agenda for what to target and in
what order. While there may be some risks involved in
formulation, if done sensitively, collaboratively, and
accounting for strengths, we suggest it can be a clinical
tool with the potential to provide considerably better out-
comes than diagnosis alone. A challenge is the integration
of a formulation-based management plan with categorical
diagnosis and the current evidence base to provide a
broad-based clinical understanding and an individualized
therapeutic strategy.
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